Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Phytomedicine ; 22(1): 213-22, 2015 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-25636891

RESUMO

Epigallocatechin gallate (EGCG), ellagic acid (EA) and rosmarinic acid (RA) are natural polyphenols exerting cancer chemopreventive effects. Ribonucleotide reductase (RR; EC 1.17.4.1) converts ribonucleoside diphosphates into deoxyribonucleoside diphosphates being essential for DNA replication, which is why the enzyme is considered an excellent target for anticancer therapy. EGCG, EA, and RA dose-dependently inhibited the growth of human HL-60 promyelocytic leukemia cells, exerted strong free radical scavenging potential, and significantly imbalanced nuclear deoxyribonucleoside triphosphate (dNTP) concentrations without distinctly affecting the protein levels of RR subunits (R1, R2, p53R2). Incorporation of (14)C-cytidine into nascent DNA of tumor cells was also significantly lowered, being equivalent to an inhibition of DNA synthesis. Consequently, treatment with EGCG and RA attenuated cells in the G0/G1 phase of the cell cycle, finally resulting in a pronounced induction of apoptosis. Sequential combination of EA and RA with the first-line antileukemic agent arabinofuranosylcytosine (AraC) synergistically potentiated the antiproliferative effect of AraC, whereas EGCG plus AraC yielded additive effects. Taken together, we show for the first time that EGCG, EA, and RA perturbed dNTP levels and inhibited cell proliferation in human HL-60 promyelocytic leukemia cells, with EGCG and RA causing a pronounced induction of apoptosis. Due to these effects and synergism with AraC, these food ingredients deserve further preclinical and in vivo testing as inhibitors of leukemic cell proliferation.


Assuntos
Antineoplásicos/farmacologia , Catequina/análogos & derivados , Cinamatos/farmacologia , Citarabina/farmacologia , Depsídeos/farmacologia , Ácido Elágico/farmacologia , Trifosfato de Adenosina/química , Catequina/farmacologia , Proliferação de Células/efeitos dos fármacos , DNA/biossíntese , Sinergismo Farmacológico , Sequestradores de Radicais Livres/farmacologia , Células HL-60/efeitos dos fármacos , Humanos , Estrutura Molecular , Inibidores da Síntese de Ácido Nucleico/farmacologia , Nucleotídeos de Timina/química , Ácido Rosmarínico
2.
Invest New Drugs ; 31(5): 1115-24, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23943154

RESUMO

Digalloylresveratrol (DIG) is a recently synthesized substance aimed to combine the effects of the natural polyphenolic compounds gallic acid and resveratrol, which both are excellent free radical scavengers with anticancer activity. In this study, we investigated the effects of DIG in the human AsPC-1 and BxPC-3 pancreatic adenocarcinoma cell lines. Treatment with DIG dose-dependently attenuated cells in the S phase of the cell cycle and led to a significant depletion of the dATP pool in AsPC-1 cells. The incorporation of (14)C-cytidine into nascent DNA of tumor cells was significantly inhibited at all DIG concentrations due to inhibition of ribonucleotide reductase, a key enzyme of DNA synthesis in tumor cells. Furthermore, Erk1/2 became inactivated and moderated p38 phosphorylation reflecting increased replication stress. DIG also activated ATM and Chk2, and induced the phosphorylation and proteasomal degradation of the proto-oncogene Cdc25A, which contributed to cell cycle attenuation. Taken together, DIG is an excellent free radical scavenger, strongly inhibits RR in situ activity, cell cycle progression, and colony formation in AsPC-1 and BxPC-3 cells thus warranting further investigations.


Assuntos
Antineoplásicos/farmacologia , Sequestradores de Radicais Livres/farmacologia , Ácido Gálico/análogos & derivados , Neoplasias Pancreáticas/tratamento farmacológico , Estilbenos/farmacologia , Compostos de Bifenilo/metabolismo , Ciclo Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Citidina/metabolismo , DNA/metabolismo , Ácido Gálico/farmacologia , Humanos , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Neoplasias Pancreáticas/metabolismo , Picratos/metabolismo , Proto-Oncogene Mas , Ribonucleotídeo Redutases/antagonistas & inibidores
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA